TABLE 3.
Series of resected pancreatic adenocarcinoma in Asian and Western Centers
| Series (Author, country) | Year | Number of Patients (N) | Median age | Gender (%) | Tumour site (%) | Stage (%) | Tumour | Lymph node (%) | Differentiation (%) | Adjuvant tx (%) | Median OS (mth) | 1‐year OS (%) | 3‐year OS (%) | 5‐year OS (%) | Prognostic Factors (multivariable analysis) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian | |||||||||||||||
| Liu et al, China 22 | 2007‐2015 | 1223 | 62 | M: 57 |
Head/Body: 56.9 Tail: 43.1 |
IA: 9.4 IB: 30.9 IIA: 15.8 IIB: 33.7 III: 10.2 |
Mean: 3.77 cm | N1: 43.9 |
WD: 65.0 MD/PD: 35.0 |
82.5 | 18.7 | 64.0 | 28.7 | NR |
Tumor grade Post‐operative (post‐op) CA 19–9 |
| Yamamoto et al, Japan 23 | 2001‐2015 | 100 | 70 | M: 58 | NR |
IA: 5 IB: 3 IIA: 38 IIB 52 III: 1 IV: 1 |
Median: 2.6 cm | N1: 53 | NR | 64.0 | NR | 79.7 | 40.9 | 22.6 | NR |
| You et al, Korea 5 | 2005‐2017 | 351 | 63.3 | M: 57.8 |
Head: 64.1 Non‐head: 32.5 Overlapping: 3.4 |
I: 19.1 II: 67.0 III: 12.8 IV: 1.1 |
NR | N1: 57.3 |
WD: 8.0 MD: 82.3 PD: 8.8 UD: 0.9 |
100.0 a | 31.7 | NR | NR | NR |
LNR Tumor grade Lymphovascular invasion (LVI) Perineural invasion (PNI) Tumor stage (T‐stage) Pre‐operative (pre‐op) CA 19‐9 |
| Xu et al, China 24 | 2010‐2014 | 353 | 61 | M: 56.9 |
Head/body: 57.5 Tail: 42.5 |
I: 24.4 IIA: 29.7 IIB: 45.9 |
Mean: 4.13 cm | N1: 45.9 |
WD/MD: 63.7 PD: 36.3 |
Chemo (82.4) ChemoRT (31.7) |
18.1 | 62.2 | 27.1 | ‐ |
Those with elevated post‐op serum CA19‐9: Tumour size, no adjuvant chemoradiotherapy (chemoRT), post‐op CA125, no decrease in CA19‐9 from pre‐op Those with normal post‐op serum CA19‐9: No adjuvant chemoradiotherapy, post‐op CA125, post‐op CEA |
| Haruki et al, Japan 25 | 2001‐2011 | 113 | 66.8 (mean) | M: 61.9 | NR |
0:6.2 I: 2.7 II: 16.8 III: 48.7 IV: 25.7 |
NR | NR | NR | NR | NR | NR | NR | 24.1 |
CRP/albumin ratio Higher TNM stage |
| Shin et al, Korea 26 | 2000‐2007 | 528 | 61 | M: 60.2 |
Head: 74.4 Non‐head: 25.6 |
≤3 cm: 51.3 >3 cm: 48.7 |
N1: 42.0 |
WD/MD: 78.0 PD: 15.2 Missing 6.8 |
NR | NR | NR | NR | 15.5 |
Tumor size Tumor grade Node‐stage (N‐stage) PNI LVI Portal/mesenteric vein invasion |
|
| Western | |||||||||||||||
| Sohn et al, USA 27 | 1984‐1999 | 616 | 64.3 (mean) | M: 54 | NR | NR | Mean: 3.2 cm | N1: 72.0 |
WD/MD: 64.0 PD: 36.0 |
74.0 | 17.0 | 63.0 | 25.0 | 17.0 |
Resection Margin Tumor size Intra‐op blood loss Tumor grade Post‐op chemoRT |
| Katz et al, USA 10 | 1990‐2002 | 329 | 64 | M: 58 |
Head: 92 Non‐head: 8 |
NR | Mean: 3.0 cm | N1: 52.0 | NR | 91.0 | 24.0 | NR | NR | 27.0 |
N‐stage Prior attempts at resection |
| Schnelldorfer et al, USA 28 | 1981‐2001 | 357 | 65 (mean) | M: 54 | Head: 100 |
IA: 7.6 IB: 14.9 IIA: 27.4 IIB: 48.5 III: 0.8 IV: 0.8 |
Mean: 3.2 cm | N1: 49.4 |
WD: 0 MD: 21.9 PD: 55.8 UD: 22.3 |
77.0 | 17.0 | NR | NR | 18.0 |
Tumour size N‐stage |
| Winter et al, USA 29 | 1990‐1999 | 399 | NR | NR | NR | NR | NR | NR | NR | NR | 25.6 | 68.0 | NR | 20.0 | ‐ |
| Winter et al, USA 29 | 2000‐2009 | 625 | NR | NR | NR | NR | NR | NR | NR | NR | 24.5 | 68.0 | NR | 8.0 | ‐ |
| Lewis et al, USA 6 | 2001–2011 | 424 | 67 | M: 50.5 | NR |
IA: 3.8 IB: 6.8 IIA: 19.3 IIB 64.9 III: 2.4 IV: 2.6 |
NR | N1: 68.4 |
WD: 10.8 MD: 49.5 PD 39.7 |
76.4 | 21.3 | 76.0 | 34.0 | 23.0 |
T‐stage N‐stage LNR Tumor size Tumor grade LVI PNI Resection margin Adjuvant treatment Pre‐op physiology |
| Konstantinidis et al, USA 30 | 1993‐2008 | 517 | 67 | M: 47.2 | NR | NR | Median: 3.0 cm | N1: 31.5 |
WD: 3.5 MD: 54.5 PD: 39.7 UD: 2.3 |
NR | 19.7 | NR | NR | 17 |
Size of tumour Tumor grade LVI PNI Resection margin LNR |
Abbreviation: CRP, C‐reactive protein; LNR, Lymph Node Ratio; LVI, Lymphovascular invasion; M, Male; MD, Moderately differentiated; NR, Not reported; PD, Poorly differentiated; PNI, Perineural invasion; UD, Undifferentiated; WD, Well differentiated
Only patients who received adjuvant chemotherapy are included in this study.